Risk of hepatitis B virus reactivation in patients treated with anti-TNFα agents for immune-mediated inflammatory diseases.

[1]  W. Seto.  Hepatitis B virus reactivation during immunosuppressive therapy: Appropriate risk stratification. , 2015, World Journal of Hepatology.

[2]  S. Boccia,et al.  HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-α) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis , 2014, International journal of rheumatology.

[3]  Gretchen A. Stevens,et al.  Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. , 2012, Vaccine.

[4]  L. López-Rosés,et al.  Hepatitis B Virus (HBV) Reactivation in Patients Receiving Tumor Necrosis Factor (TNF)-Targeted Therapy: Analysis of 257 Cases , 2011, Medicine.

[5]  T. Hsieh,et al.  Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy , 2011 .

[6]  D. Vassilopoulos,et al.  Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection , 2010, Annals of the rheumatic diseases.

[7]  C. Charpin,et al.  Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients , 2009, Arthritis research & therapy.

[8]  J. Hoofnagle,et al.  Management of hepatitis B: Summary of a clinical research workshop , 2007, Hepatology.

[9]  S. Bae,et al.  Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. , 2013, Clinical and experimental rheumatology.